Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for resectable esophageal squamous cell carcinoma
ChiCTR2400086654Phase 2Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Beijing Friendship Hospital. Primary endpoint: Major pathological response rate. Started Jul 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400086654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086654.